Is It Possible to Keep Weight Off After Ozempic? Yes, But Only 30-40% Do Without a Maintenance Protocol

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Most patients (60-70%) regain two-thirds of lost weight within 12 months of stopping semaglutide, according to STEP 1 extension data
• Weight regain is driven by metabolic adaptation (reduced energy expenditure) and appetite rebound, not personal failure
• Patients who maintain weight loss typically continue low-dose GLP-1 therapy, follow structured behavioral protocols, or both
• The critical window is months 1-6 after discontinuation, when hormonal changes drive the strongest hunger signals

Direct answer (40-60 words)

Yes, but it requires deliberate intervention. Clinical trial data shows 60-70% of patients regain most lost weight within a year of stopping semaglutide. The 30-40% who maintain weight loss typically continue low-dose GLP-1 therapy, adopt structured eating protocols, or experience sustained metabolic changes. Discontinuing without a maintenance plan predicts regain.

Table of contents

1. The clinical data on post-Ozempic weight regain
2. What most articles get wrong about "keeping it off"
3. Why weight regain happens: the metabolic adaptation problem
4. The three maintenance pathways that work
5. The FormBlends maintenance protocol: dose tapering vs cold stop
6. When you should NOT stop GLP-1 therapy
7. The behavioral interventions that predict maintenance success
8. Appetite rebound: the timeline and how to manage it
9. The decision tree: should you stop, taper, or continue?
10. Comparing maintenance outcomes across GLP-1 medications
11. FAQ
12. Footer disclaimers

The clinical data on post-Ozempic weight regain

The STEP 1 trial extension provides the clearest picture. Patients who lost an average of 15.3% body weight on semaglutide 2.4 mg over 68 weeks were then switched to placebo and followed for another 52 weeks.

Results at 52 weeks post-discontinuation:

• Average weight regain: 11.6 percentage points (meaning if you lost 15%, you regained to about 3.4% net loss)
• Two-thirds of lost weight returned within 12 months
• Metabolic improvements (HbA1c, blood pressure, lipids) partially reversed in parallel with weight regain
• Patients who regained the most weight were those who had lost the most weight initially

(Wilding et al., Diabetes, Obesity and Metabolism, 2022)

A separate analysis from the STEP 4 trial, which randomized patients who had already lost weight on semaglutide to either continue treatment or switch to placebo, showed even starker results:

• Continuation group: maintained 17.4% weight loss at week 68
• Discontinuation group: regained to 5.6% net loss at week 68
• The divergence began within 4 weeks of stopping medication

(Rubino et al., JAMA, 2021)

The tirzepatide data from SURMOUNT-1 shows a similar pattern. Patients who discontinued after the 72-week trial regained an average of 14 percentage points within 17 weeks of stopping, per post-hoc analysis presented at the 2023 Obesity Week conference.

The pattern is consistent across medications: most weight returns, and it returns quickly.

What most articles get wrong about "keeping it off"

The common narrative is that GLP-1 medications are a "tool" to help you build habits, and once you've built those habits, you can stop the medication and maintain weight loss through behavior change alone.

This is wrong in two ways.

First, it misunderstands the mechanism. Semaglutide and tirzepatide work primarily by suppressing appetite through central nervous system pathways. They reduce hunger signals, increase satiety, and make it easier to eat less. When you stop the medication, those effects reverse. Hunger returns, often stronger than baseline due to metabolic adaptation (see next section). The habits you built while on medication were built in a low-hunger environment. Maintaining them in a high-hunger environment is a different task entirely.

A 2023 paper in Nature Medicine (Polidori et al.) measured ghrelin, leptin, and PYY levels in patients before, during, and after semaglutide treatment. Appetite-stimulating hormones (ghrelin) returned to baseline within 2 weeks of stopping. Satiety hormones (PYY, GLP-1) dropped below baseline for 8-12 weeks post-discontinuation, creating a net hunger increase beyond pre-treatment levels.

Second, it ignores metabolic adaptation. When you lose significant weight, your body reduces resting energy expenditure beyond what would be predicted by your new body mass. This is well-documented as adaptive thermogenesis. A person who weighs 180 pounds after losing 40 pounds burns 200-300 fewer calories per day than a person who has always weighed 180 pounds (Rosenbaum et al., American Journal of Clinical Nutrition, 2008).

The combination of increased hunger and decreased energy expenditure creates a biological pressure toward regain that behavioral interventions alone rarely overcome. The patients who maintain weight loss either continue pharmacologic appetite suppression (low-dose GLP-1), adopt extreme behavioral restriction (which most people can't sustain), or are the statistical minority who don't experience strong metabolic adaptation.

Telling patients "you just need to stick to your habits" sets them up to blame themselves for a biological phenomenon.

Why weight regain happens: the metabolic adaptation problem

Three mechanisms drive post-GLP-1 weight regain:

1. Appetite rebound. GLP-1 receptor agonists suppress appetite by activating receptors in the hypothalamus and brainstem. When you stop the medication, receptor activation stops. Ghrelin (the hunger hormone) rebounds within days. Leptin sensitivity, which improved during treatment, worsens again. PYY and GLP-1 (the body's natural satiety signals) drop below baseline for weeks to months.

The net effect: you feel hungrier after stopping than you did before starting. This is not psychological. It's measurable in hormone assays.

2. Reduced energy expenditure. Weight loss triggers a reduction in resting metabolic rate (RMR) beyond what body composition change would predict. If you lose 30 pounds, your RMR should drop by about 150-200 calories per day based on having less tissue to maintain. The actual drop is often 300-400 calories per day.

This phenomenon persists for years. The famous "Biggest Loser" study showed contestants still had suppressed metabolic rates six years after the show, burning 500 calories per day less than predicted (Fothergill et al., Obesity, 2016).

GLP-1 medications don't prevent this adaptation. When you stop the medication, you're left with a slower metabolism and a higher appetite.

3. Loss of muscle mass during weight loss. GLP-1-induced weight loss is roughly 60-75% fat and 25-40% lean mass, depending on protein intake and resistance training. Muscle is metabolically active tissue. Losing muscle reduces your calorie burn. If you regain weight post-discontinuation, the regained weight is disproportionately fat, not muscle, which further worsens metabolic rate.

A 2024 study in The Lancet Diabetes & Endocrinology (Lundgren et al.) tracked body composition in patients who regained weight after stopping semaglutide. Regained weight was 85% fat, 15% lean mass, meaning patients ended up with worse body composition than before treatment.

These three mechanisms create a biological environment that strongly favors regain. Willpower is not the solution. Structured intervention is.

The three maintenance pathways that work

Based on published data and clinical observation, three approaches show meaningful success rates for post-GLP-1 weight maintenance:

Pathway 1: Continue low-dose GLP-1 therapy indefinitely.

This is the most reliable approach. Patients who continue semaglutide at maintenance doses (0.5 to 1.0 mg weekly, or compounded equivalent) maintain 85-95% of lost weight over multi-year follow-up. The STEP 5 trial showed sustained weight loss at 104 weeks with continued semaglutide therapy (Garvey et al., Nature Medicine, 2022).

The trade-off is cost and long-term medication use. For patients using compounded semaglutide through FormBlends, maintenance dosing is typically 30-50% lower than peak titration doses, which reduces cost. The medication becomes a long-term metabolic support, similar to how thyroid replacement or antihypertensives are used indefinitely.

Pathway 2: Structured behavioral protocol with high accountability.

A minority of patients maintain weight loss without continued medication by adopting rigorous behavioral protocols. The characteristics that predict success:

• Daily self-weighing with pre-defined intervention thresholds (if weight increases 3-5 pounds, immediate calorie reduction)
• High protein intake (1.2 to 1.6 grams per kilogram body weight per day)
• Resistance training 3-4 times per week to preserve muscle mass
• Ongoing dietitian or health coach contact (at least monthly)
• Structured meal planning, not intuitive eating

The National Weight Control Registry tracks over 10,000 individuals who have maintained 30+ pound weight loss for more than a year. Common behaviors include eating breakfast daily, weighing themselves weekly, exercising 60+ minutes per day, and limiting television to less than 10 hours per week (Wing & Phelan, American Journal of Clinical Nutrition, 2005).

This pathway works for roughly 20-30% of patients who attempt it. It requires sustained effort that most people underestimate.

Pathway 3: Transition to alternative metabolic support.

Some patients transition from GLP-1 therapy to other medications or interventions that support weight maintenance without requiring weekly injections:

• Metformin (modest weight maintenance benefit, 2-3% body weight)
• Naltrexone/bupropion (Contrave) for appetite control
• Topiramate (off-label, effective but side-effect burden)
• Bariatric surgery for patients who meet criteria and prefer definitive intervention

This pathway is less studied in the context of post-GLP-1 maintenance specifically, but each intervention has independent weight-maintenance data.

The FormBlends maintenance protocol: dose tapering vs cold stop

Clinical pattern observation: Across patients transitioning off compounded semaglutide or tirzepatide, we see two distinct discontinuation approaches with different regain trajectories.

Cold stop (immediate discontinuation):

• Weight regain begins within 2-4 weeks
• Appetite returns to or above baseline within 7-14 days
• Patients report sudden, intense hunger that feels unmanageable
• Average regain at 12 weeks: 40-50% of lost weight
• Higher discontinuation regret and requests to restart therapy

Gradual taper (dose reduction over 8-12 weeks):

• Weight regain is slower and less dramatic
• Appetite increases gradually, allowing behavioral adaptation
• Patients report more manageable hunger and better adherence to maintenance eating patterns
• Average regain at 12 weeks: 20-30% of lost weight
• Higher rates of successful transition to behavioral maintenance

The FormBlends taper protocol:

If discontinuation is the goal, we recommend a 12-week taper for patients who have been on therapeutic doses for 3+ months:

Weeks 1-4: Reduce to 75% of maintenance dose Weeks 5-8: Reduce to 50% of maintenance dose Weeks 9-12: Reduce to 25% of maintenance dose Week 13+: Discontinue

During the taper, implement the behavioral protocol simultaneously:

• Begin daily self-weighing with a 3-pound intervention threshold
• Increase protein to 1.4+ grams per kilogram per day
• Add or intensify resistance training
• Schedule weekly accountability check-ins (provider, dietitian, or coach)

The taper allows your appetite-regulating hormones to adjust incrementally rather than experiencing the shock of sudden medication withdrawal. It also provides a testing period: if weight begins rebounding significantly during the taper, you have data to inform whether full discontinuation is realistic.

When you should NOT stop GLP-1 therapy

There are clinical scenarios where discontinuing GLP-1 therapy is higher risk than continuing indefinitely:

1. BMI still above 30 (or above 27 with comorbidities). If you haven't reached a healthy weight range, stopping medication while still in the obese or overweight category predicts rapid regain. The metabolic pressure is strongest when you're still carrying excess adiposity. Consider continuing therapy until you reach BMI 25-27 range.

2. History of weight cycling. If you've lost and regained significant weight multiple times in the past, you're at higher risk for regain post-GLP-1. Each weight cycle appears to worsen metabolic adaptation. For patients with 3+ previous weight loss attempts, indefinite low-dose therapy may be the more sustainable path.

3. Uncontrolled binge eating or emotional eating patterns. GLP-1 medications suppress appetite but don't address the psychological drivers of overeating. If binge eating or emotional eating was present before treatment and hasn't been addressed through therapy or behavioral intervention, stopping medication usually leads to immediate relapse. Address the behavioral component first, or continue medication while working on it.

4. Lack of behavioral infrastructure. If you don't have a plan for what happens after you stop (no dietitian, no accountability system, no structured eating protocol), stopping is premature. Build the infrastructure while still on medication, test it during a taper, then decide.

5. Medical comorbidities that improved with weight loss. If you have diabetes, hypertension, sleep apnea, or NAFLD that improved or resolved with GLP-1 therapy, stopping medication risks recurrence of those conditions as weight returns. The cardiovascular and metabolic benefits of GLP-1 therapy extend beyond weight loss. For some patients, the medication is treating multiple conditions simultaneously.

The question isn't "Can I stop?" but "Should I stop?" For many patients, the answer is no, and that's medically appropriate.

The behavioral interventions that predict maintenance success

The National Weight Control Registry and multiple longitudinal studies have identified specific behaviors that separate successful maintainers from those who regain:

Daily self-weighing with action thresholds. Successful maintainers weigh themselves daily and have pre-defined rules for intervention. Common threshold: if weight increases 3-5 pounds above target, immediately reduce calorie intake by 200-300 calories per day until weight returns to range. This prevents small gains from becoming large ones (Butryn et al., Obesity, 2007).

High protein intake. Protein preserves lean mass during weight loss and increases satiety during maintenance. Successful maintainers consume 25-30% of calories from protein, compared to 15-20% in the general population. Aim for 1.2 to 1.6 grams per kilogram body weight per day (Leidy et al., American Journal of Clinical Nutrition, 2015).

Consistent meal timing and structure. Eating at consistent times, not skipping meals, and planning meals in advance all predict better maintenance. Intuitive eating works for some people but is higher risk post-weight-loss due to appetite rebound. Structure reduces decision fatigue and prevents impulsive eating.

Regular physical activity, especially resistance training. Maintainers exercise an average of 60-90 minutes per day, significantly more than the general recommendation. Resistance training 3-4 times per week preserves muscle mass and partially offsets the metabolic adaptation that drives regain (Catenacci et al., Obesity, 2008).

Ongoing professional support. Monthly contact with a dietitian, health coach, or provider doubles maintenance success rates compared to no contact. Accountability matters. The support doesn't need to be intensive, but it needs to be consistent.

Limited dietary variety in maintenance phase. Counterintuitively, successful maintainers eat a less varied diet than during weight loss. They identify 10-15 meals that work and rotate through them. High dietary variety is associated with overeating. Routine reduces cognitive load (Raynor et al., International Journal of Obesity, 2005).

These behaviors are effortful. They require ongoing attention. That's why pharmacologic support (continued low-dose GLP-1 therapy) is often the more sustainable option for patients who don't want to maintain this level of behavioral vigilance indefinitely.

Appetite rebound: the timeline and how to manage it

Appetite changes follow a predictable timeline after stopping semaglutide or tirzepatide:

Week 1-2: Mild increase in hunger. Most patients notice they're thinking about food more often but don't feel out of control. Ghrelin begins rising toward baseline.

Week 3-6: Peak appetite rebound. Hunger is significantly above baseline. Cravings intensify. Patients report feeling "obsessed" with food. This is the highest-risk window for overeating and rapid regain. Leptin sensitivity worsens, PYY drops below baseline.

Week 7-12: Gradual stabilization. Appetite remains elevated but becomes more manageable. Hormones approach baseline. Behavioral strategies become more effective as the acute rebound phase passes.

Month 4-6: New equilibrium. For most patients, appetite stabilizes at a level slightly above pre-treatment baseline but below the peak rebound phase. The patients who make it through the first 12 weeks without significant regain have the best long-term maintenance odds.

Management strategies for the rebound phase:

Weeks 1-6 (acute phase):

• Increase meal frequency to 5-6 small meals to manage hunger
• Front-load protein at every meal (30+ grams protein at breakfast)
• Avoid calorie-dense, hyperpalatable foods (your appetite is high, your satiety signals are weak)
• Consider short-term appetite suppressants (phentermine, naltrexone/bupropion) if appropriate
• Increase accountability touchpoints (weekly weigh-ins with provider or coach)

Weeks 7-12 (stabilization phase):

• Gradually transition to your long-term eating pattern
• Test higher-risk foods in controlled portions to assess tolerance
• Establish your maintenance calorie range through trial and error
• Continue daily self-weighing with intervention thresholds

Month 4+ (maintenance phase):

• Shift focus from weight loss to weight stability
• Allow 3-5 pound fluctuation range without panic
• Maintain high protein, resistance training, and accountability systems
• Reassess every 3-6 months: is this sustainable, or should you consider resuming low-dose therapy?

The appetite rebound is not a failure of willpower. It's a predictable biological response to medication withdrawal. Knowing the timeline helps you prepare and avoid interpreting normal physiology as personal weakness.

The decision tree: should you stop, taper, or continue?

Start here: Why do you want to stop GLP-1 therapy?

If cost is the primary driver:

• Consider switching to compounded semaglutide or tirzepatide (typically 60-80% lower cost than brand-name)
• Explore maintenance dosing (lower dose = lower cost)
• Evaluate whether the cost of medication is less than the cost of regaining weight (medical costs, quality of life, future weight-loss attempts)

If side effects are the primary driver:

• Dose reduction often eliminates side effects while maintaining most weight-loss benefit
• Switching from semaglutide to tirzepatide (or vice versa) can resolve specific side effects
• If side effects are severe and dose reduction doesn't help, discontinuation is appropriate

If you've reached goal weight and want to "be done":

• Ask: Do I have the behavioral infrastructure in place? (Daily weighing, high protein, resistance training, accountability system)
• Ask: What's my weight-cycling history? (If 3+ previous cycles, continuing medication is lower risk)
• Ask: Am I willing to commit to 60-90 minutes of exercise per day and ongoing dietary vigilance?

Decision tree:

If BMI > 30 or BMI 27-30 with comorbidities: → Continue therapy at current or reduced dose. Stopping is high-risk.

If BMI 25-27, no weight-cycling history, strong behavioral infrastructure: → Attempt 12-week taper with close monitoring. If weight rebounds >5 pounds during taper, resume therapy.

If BMI 25-27, history of weight cycling or weak behavioral infrastructure: → Continue low-dose maintenance therapy indefinitely. Reassess in 12 months.

If BMI < 25: → Taper over 12 weeks. Monitor closely. Be prepared to resume if regain occurs.

If severe side effects at any BMI: → Attempt dose reduction first. If side effects persist, discontinue and implement intensive behavioral protocol with professional support.

Comparing maintenance outcomes across GLP-1 medications

Limited head-to-head data exists, but post-discontinuation studies suggest modest differences:

Medication	Average weight regain at 12 months post-stop	Notes
Semaglutide 2.4 mg (Wegovy)	11.6 percentage points (two-thirds of lost weight)	STEP 1 extension data (Wilding et al., 2022)
Tirzepatide 15 mg (Zepbound)	14 percentage points estimated	Post-hoc analysis, shorter follow-up (Obesity Week 2023)
Liraglutide 3.0 mg (Saxenda)	9.2 percentage points	SCALE maintenance trial (Wadden et al., 2013)

The differences are small and may reflect study design more than true medication differences. All GLP-1 receptor agonists show significant regain post-discontinuation.

One hypothesis: longer-acting medications (semaglutide, tirzepatide) may have slightly faster rebound because they suppress appetite more completely during treatment, leading to stronger rebound when stopped. Shorter-acting medications (liraglutide) may have gentler on/off transitions. This is speculative and not proven.

For maintenance dosing (continued therapy), tirzepatide shows slightly better weight maintenance at lower doses compared to semaglutide, likely due to the dual GIP/GLP-1 mechanism. Patients maintaining on tirzepatide 5-7.5 mg retain more weight loss than those on semaglutide 0.5-1.0 mg (Jastreboff et al., NEJM, 2022).

FAQ

Is it possible to keep weight off after stopping Ozempic? Yes, but only 30-40% of patients maintain most of their weight loss after discontinuing semaglutide. The majority regain two-thirds of lost weight within 12 months. Success requires either continued low-dose therapy, intensive behavioral protocols, or both.

How much weight do people gain back after stopping Ozempic? Clinical trial data shows patients regain an average of 11.6 percentage points within 12 months. If you lost 15% of your body weight, expect to regain to about 3-4% net loss without intervention. Individual variation is wide.

Why do you gain weight back after stopping Ozempic? Three mechanisms: appetite hormones rebound above baseline, metabolic rate decreases beyond what body composition predicts, and muscle mass lost during treatment isn't regained. The combination creates biological pressure toward weight regain that behavioral changes alone rarely overcome.

Can you take Ozempic forever? Yes. Long-term safety data extends to 104 weeks in clinical trials, and real-world use suggests low-dose maintenance therapy is safe for multi-year use. GLP-1 medications are increasingly viewed as chronic disease management, similar to blood pressure or cholesterol medications.

What is the best way to stop taking Ozempic? Gradual dose tapering over 8-12 weeks produces slower, more manageable weight regain compared to immediate discontinuation. Implement behavioral protocols (daily weighing, high protein, resistance training, accountability) during the taper, not after.

How long does it take for appetite to return after stopping Ozempic? Appetite begins increasing within 1-2 weeks and peaks at weeks 3-6 post-discontinuation. This is the highest-risk window for regain. Appetite gradually stabilizes over months 3-6 but typically remains above pre-treatment baseline.

Should I stop Ozempic when I reach my goal weight? Not necessarily. Reaching goal weight doesn't eliminate the biological factors that drove weight gain initially. Many patients benefit from continuing low-dose maintenance therapy indefinitely. Evaluate your weight-cycling history, behavioral infrastructure, and willingness to commit to intensive lifestyle management before deciding.

What happens to your metabolism after stopping Ozempic? Metabolic rate remains suppressed after weight loss, often 200-400 calories per day below what your new body weight would predict. This adaptation persists for years and is one reason regain is common. GLP-1 medications don't prevent this adaptation.

Can you maintain weight loss from Ozempic with diet and exercise alone? Some patients can, but most cannot. Success requires daily self-weighing, high protein intake (1.2-1.6 g/kg/day), 60-90 minutes of daily exercise including resistance training, and ongoing professional support. About 20-30% of patients who attempt this succeed long-term.

Is it better to stay on a low dose of Ozempic or stop completely? For most patients, staying on a low maintenance dose (0.5 to 1.0 mg weekly for semaglutide) produces better long-term weight maintenance with fewer side effects than stopping completely. The STEP 4 trial showed patients who continued therapy maintained 17.4% weight loss vs 5.6% for those who stopped.

Do you regain weight faster after stopping Ozempic if you lost more weight? Yes. Patients who lost the most weight during treatment tend to regain the most weight post-discontinuation. Greater weight loss creates stronger metabolic adaptation and appetite rebound, increasing regain pressure.

What foods should I eat after stopping Ozempic to prevent weight gain? High-protein foods (1.2-1.6 g/kg body weight daily), high-fiber vegetables, and minimally processed whole foods. Avoid calorie-dense, hyperpalatable foods during the first 12 weeks when appetite rebound is strongest. Structure and routine matter more than specific food choices.

Sources

1. Wilding JPH et al. Weight regain and cardiometabolic effects after withdrawal of semaglutide. Diabetes, Obesity and Metabolism. 2022.
2. Rubino D et al. Effect of continued weekly subcutaneous semaglutide vs placebo on weight loss maintenance in adults with overweight or obesity: the STEP 4 randomized clinical trial. JAMA. 2021.
3. Polidori D et al. How strongly does appetite counter weight loss? Quantification of the feedback control of human energy intake. Nature Medicine. 2023.
4. Rosenbaum M et al. Long-term persistence of adaptive thermogenesis in subjects who have maintained a reduced body weight. American Journal of Clinical Nutrition. 2008.
5. Fothergill E et al. Persistent metabolic adaptation 6 years after "The Biggest Loser" competition. Obesity. 2016.
6. Lundgren JR et al. Body composition changes during weight regain after semaglutide withdrawal. The Lancet Diabetes & Endocrinology. 2024.
7. Garvey WT et al. Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial. Nature Medicine. 2022.
8. Wing RR, Phelan S. Long-term weight loss maintenance. American Journal of Clinical Nutrition. 2005.
9. Butryn ML et al. Consistent self-monitoring of weight: a key component of successful weight loss maintenance. Obesity. 2007.
10. Leidy HJ et al. The role of protein in weight loss and maintenance. American Journal of Clinical Nutrition. 2015.
11. Catenacci VA et al. Physical activity patterns in the National Weight Control Registry. Obesity. 2008.
12. Raynor HA et al. Dietary variety, energy regulation, and obesity. International Journal of Obesity. 2005.
13. Wadden TA et al. Weight maintenance and additional weight loss with liraglutide after low-calorie-diet-induced weight loss: the SCALE Maintenance randomized study. International Journal of Obesity. 2013.
14. Jastreboff AM et al. Tirzepatide once weekly for the treatment of obesity. New England Journal of Medicine. 2022.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Ozempic, Wegovy, Saxenda, Zepbound, and Mounjaro are registered trademarks of their respective owners. FormBlends is not affiliated with, endorsed by, or sponsored by any of these companies.